Ardelyx Inc. Comparables
Find the most relevant public market comparables for Ardelyx Inc., including EV/Revenue and EV/EBITDA multiples to help you make informed investment decisions.
Company Overview
Ardelyx Inc. is a biopharmaceutical company that discovers, develops, and commercializes minimally-systemic small molecule therapeutics for the gastrointestinal (GI) tract to treat cardio-renal, GI, and metabolic diseases. They develop and commercialize first-in-class medicines to meet unmet medical needs. They have two commercial products approved in the United States: IBSRELA (tenapanor) and XPHOZAH (tenapanor).
Business Model
Discovery, development, and commercialization of small molecule therapeutics for cardio-renal, gastrointestinal, and metabolic disorders.
Target Customers
Patients in the US with conditions such as irritable bowel syndrome with constipation (IBS-C) and chronic kidney disease on dialysis.
Specific Focus
First-in-class, novel mechanism therapies for cardio-renal, gastrointestinal, and metabolic diseases.
Location
Waltham, Massachusetts
CEO
Mike Raab
Industry
Life sciences
Sub Sector
Biopharmaceuticals
3yr Revenue Growth
1,544%
Website
Public Market Comparables
Below are the key valuation metrics for companies similar to Ardelyx Inc. in the Pharmaceuticals sector. These metrics can help you understand how the market values companies with similar business models and growth profiles.
Looking for a comprehensive compset for Ardelyx Inc.? Our platform provides detailed analysis of Ardelyx Inc.'s competitive landscape, including financial metrics, growth trends, and market positioning. Get access to the full Ardelyx Inc. compset by trying our platform today.
EV/Revenue Multiple
Min
0.0x
Median
0.0x
Max
00.0x
Unlock actual values by trying our platform
View Full DetailsEV/EBITDA Multiple
Min
00.0x
Median
00.0x
Max
00.0x
Unlock actual values by trying our platform
View Full Details
Unlock the Full Ardelyx Inc. Compset
As a leading player in the Life sciences industry within the Pharmaceuticals sector, Ardelyx Inc. operates in the specialized Biopharmaceuticals sub-sector. Understanding how Ardelyx Inc. compares to its public market comps is essential for accurate valuation and strategic decision-making.
Our comprehensive analysis includes detailed comparables (compsets) featuring similar companies in the Biopharmaceuticals space, with complete financial metrics, growth trajectories, and competitive positioning insights that go beyond the surface-level data shown above.
Other Interesting Companies
TG Therapeutics, Inc.
Healthcare • Life sciences
TG Therapeutics, Inc. is a fully integrated, commercial-stage biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. They have received FDA approval for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis.
Vytalize Health
Healthcare • Life sciences
Vytalize Health is a risk-bearing provider enablement platform and leading Accountable Care Organization (ACO) that partners with primary care physicians (PCPs) to deliver value-based care, improving patient outcomes and reducing healthcare costs. They offer an all-in-one solution including value-based incentives, smart technology, and a virtual clinic, enabling independent practices to thrive in value-based care arrangements. The company focuses on Medicare patients and works with over 2,500 PCPs across 36 states.
Talkiatry
Healthcare • Life sciences
Talkiatry is a national mental health practice providing in-network psychiatry and therapy via telehealth. It utilizes technology and a human-centered approach to improve access to high-quality mental healthcare, addressing issues of accessibility and affordability.
Get Your Custom Comparable Analysis
Need a more detailed analysis of Ardelyx Inc. and its public market comparables? Our platform provides comprehensive valuation metrics, growth analysis, and more.
Try CompsetFinder Free